Exome sequencing identifies a novel \textit{GUCY2D} mutation in an Iranian family with Leber congenital amaurosis-1: a case report

Mostafa Neissi$^{1,2,*}$, Adnan Issa Al-Badran$^3$ and Javad Mohammadi-Asl$^4$

Abstract

\textbf{Background:} Leber congenital amaurosis (LCA), the severe form of inherited retinal degenerative disorder, is a prevalent disorder in the first year of life. Recently, genetic studies discovered that different gene mutations are responsible for LCA clinical manifestations.

\textbf{Case presentation:} In this study, we applied whole exome sequencing (WES) to identify probable gene defects in an Iranian girl with LCA-1. We found a novel disease-causing \textit{GUCY2D} gene mutation (c.2348T > C; p.L783P), located in exon 12 (NM_000180), causing a missense mutation that has been changed the coding protein. The WES-identified variant was confirmed by Sanger sequencing for the patient and her healthy parents. Submitted to genetic counseling that the patient was 1-year old and blindness from birth.

\textbf{Conclusions:} Our findings establish that this detected \textit{GUCY2D}-p.L783P mutation is the pathogenic variant for LCA-1. This is the first genetic study indicating that c.2348T > C missense mutation in the homozygous state in \textit{GUCY2D} gene is responsible for the LCA-1 phenotype.

\textbf{Keywords:} Leber congenital amaurosis, \textit{GUCY2D}, Novel mutation, Whole exome sequencing (WES), Case report

Background

Leber congenital amaurosis (LCA) is the most severe form of inherited retinal dystrophy that diagnosed with blindness or severe visual impairment before the first year of age [1, 2]. LCA is an autosomal recessive disorder with the prevalence rate of one patient in every 80,000 people around the world [3].

Etiologically, childhood blindness can be triggered from different risk factors such as genetic and chromosomal abnormalities, and intrauterine infections. [4]. Studies have shown that genetic factors are responsible for more than 50% of all types of eye diseases [5]. Genetic eye diseases include a large number of ocular complications that can be passed from parents to children [6].

Previously, it has been identified that genetic abnormality in a group of genes included \textit{GUCY2D}, \textit{RPE65}, \textit{RPGRIP1}, \textit{AIPL1}, \textit{CRB1}, \textit{NMNAT1}, and \textit{CEP290} associated with LCA cases; however, more studies demonstrated that there are 26 genes related to the LCA [7, 8]. On the other hand, it has been determined that recessive and dominant mutations in the \textit{GUCY2D} gene were the underlying defects in LCA-1 and cone-rod degeneration, respectively [9, 10]. The \textit{GUCY2D} gene is composed of 20 exons, located on the short arm of chromosome 17 (17p13.1) and encodes a 1,103-amino acids protein named retinal guanylyl cyclase-1 (RetGC-1) [10].

Moreover, the whole exome sequencing (WES) technique is a perfect diagnostic method in these cases...
that compares the obtained results with the reference sequences. Therefore, it is able to identify disease-causing mutations in affected patients [11].

We reported here an Iranian patient affected by LCA-1 with blindness. To identify the underlying genetic defect, in this case, we performed WES followed by a targeted sequencing approach.

Case presentation

We have enrolled an Iranian family with LCA-1 from the Ahvaz (Khuzestan province, Iran). The patient was a 1-year-old girl with no light perception (NLP) blindness (Fig. 1A). Clinical examination was performed by neuro-ophthalmologists and confirmed as a blindness case by visual evoked potentials (VEPs) test. The patient's problem was blindness at the beginning of her life, as her parents were mentioned to the genetic counseling. Other clinical complication was retinal degeneration throughout the retina in both eyes. She was born to consanguineous normal parents, and there was no family history of inherited diseases such as LCA.

Total genomic DNA (gDNA) was extracted from peripheral blood leukocytes sample of the patient and her family members using a standard salting-out protocol. WES (Macrogen, Seoul, South Korea) was conducted to detect mutations in particular genes to hereditary this type of eye disease in the gDNA of the proband. A novel single-nucleotide variant (NM_000180: c.2348T > C; p.L783P) was detected in exon 12 of the GUCY2D gene. No mutation was detected in other genes.

The frequency (below 1%) of the detected variants were checked in the 1000 genomes database (https://www.internationalgenome.org/), exome aggregation consortium (ExAC), and single-nucleotide polymorphism database (dbSNP). In silico analyses using Sort Intolerated From Tolerated (SIFT), Polymorphism Phenotyping v2 (PolyPhen-2), and Mutation Taster predicted that L783P variant would be damaging and disease-causing. Also, the mutation has been classified as likely pathogenic based on American College of Medical Genetics and Genomics (ACMG) guidelines. Finally, the candidate variant was checked by both ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) and the Human Gene Mutation Database (HGMD, http://www.hgmd.cf.ac.uk/ac/index.php). This is the first report of mutation of the GUCY2D gene in a patient affected by LCA-1.

The candidate mutation (c.2348T > C) was confirmed by sanger sequencing for the patient and family members. In order to amplify the GUCY2D-Specific genomic DNA fragments, the polymerase chain reaction (PCR) method was used. The results demonstrated that the affected case was homozygous for this novel mutation and her parents...
carried a heterozygous \textit{GUCY2D} c.2348T > C (p.L783P) variant (Fig. 1B). This missense mutation causes variation in amino acid from leucine to proline (CTG > CCG) at codon 783 (Fig. 1C).

**Discussion**

LCA is a major concern among different types of inherited retinal blindness due to its devastating severity [1]. Although genetic consulting for consanguine parents is highly recommended, we are still witnessing the birth of babies with congenital disorders [1, 3, 12]. So far, studies on genetic defects of LCA indicated that about 70% of patients suffered from a molecular disease-causing event. As the recent efforts focused on the new therapeutic strategies such as gene replacement therapy, finding the underlying genetic problem in affected patients is a very important issue [1].

Hence, in this study, we investigated for the disease-causing mutation in a 1-year-old affected girl, who was referred to medical genetics for no light perception (NLP) blindness. The patient was belonging to consanguineous healthy parents with no history of inherited disorders. The WES was applied to identify the impaired gene in this case and a homozygous missense mutation (c.2348T > C; p.Leu783Pro) in the exon 12 of the \textit{GUCY2D} gene was detected, followed by heterozygous mutations in her consanguine parents that resulted in homogeneity in their child.

The \textit{GUCY2D} gene located in chromosome 17, encodes retGC-1 protein that plays a critical role in restoring photoreceptor sensitivity by converting guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP) [10]. It was declared that \textit{GUCY2D} gene mutations accounted for about 6%–21% of all LCA cases [13]. Considering the most of 127-point mutations detected so far in \textit{GUCY2D} gene can affect all retGC-1 domains and subsequently result in LCA phenotype [9, 13]; our finding also added another novel missense mutation in \textit{GUCY2D} gene leading to LCA-1 disorder.

We proposed that this novel missense mutation encodes an impaired form of retGC-1 protein that probably defects in function or stability resulting in LCA-1 clinical manifestations. In addition, it has been described previously that the LCA-1 phenotype caused by mutations in the retGC-1, dramatically reduced retGC-1 activity [9, 13]. So that, in a study, Xue Feng et al. evaluated a Chinese family with LCA-1 to determine underlying genetic defect and showed that there were three novel mutation in the \textit{GUCY2D} gene result in truncated protein or activity reduction [13]. In another investigation, Libe Gradstein et al. described a novel mutation in \textit{GUCY2D} gene as well as other known mutations in eight affected LCA patients. In addition, molecular modeling approaches implied that loss of retGC-1 helical structure because of the c.2129C > T; p.Ala710Val mutation in the \textit{GUCY2D} gene, which is likely to affect the catalytic center [14].

Finally, the \textit{GUCY2D}-p.L783P mutation was identified in an Iranian patient affected by LCA-1 and has not been previously reported in any of the mutation databases. We have four pieces of evidence proves that this mutation can lead to LCA-1: 1. Only this mutation was detected by WES and could be the main cause of LCA-1. 2. Bioinformatics tools such as SIFT, PolyPhen-2 and Mutation taster confirmed that this variant was predicted to be damaging and disease-causing. 3. According to the samples analyzed by direct Sanger sequencing (Fig. 1B), the presence of this mutation was proved in the patient, and the pattern of inheritance must be an autosomal recessive for the \textit{GUCY2D} gene because the patient carries a homozygous mutation and her consanguine parents are heterozygous for the detected mutation. 4. A point mutation c.2348T > C of the \textit{GUCY2D} gene, in exon 12 causes substitution of leucine by proline at position 783 which would be expected to affect retGC-1 function.

**Conclusion**

The present study detected a case of LCA-1 with a novel homozygous \textit{GUCY2D} gene mutation (c.2348T > C; p.L783P) in an Iranian girl from a heterozygous and carrier parents using WES technique. It can be concluded that this point of detected mutation is a novel mutational hotspot point that carried in patient ancestors. Moreover, our findings confirm previous reports that mutation in \textit{GUCY2D} gene is associated with LCA disease, and we show that this method can be useful for identifying rare causative genetic variants in LCA patients.

**Abbreviations**

ACMG: American College of Medical Genetics and Genomics; cGMP: Cyclic guanosine monophosphate; dbSNP: Single nucleotide polymorphism database; ExAC: Exome aggregation consortium; gDNA: Genomic DNA; GTP: Guanosine triphosphate; HGMD: Human gene mutation database; LCA: Leber congenital amaurosis; NLP: No light perception; PCR: Polymerase chain reaction; PolyPhen-2: Polymorphism phenotyping v2; RetGC-1: Retinal guanylyl cyclase-1; SIFT: Sort intolerated from tolerated; WES: Whole exome sequencing; VEPs: Visual evoked potentials.

**Acknowledgements**

The authors would like to thank the family members for their participation in this study.

**Authors’ contributions**

MN made design of the study and wrote the manuscript. MN, AIA and JMA analyzed and interpreted the data. All authors have read and approved the final manuscript.

**Funding**

There is no financial support.
Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate
Written informed consent was obtained from the parents of the patient, and the study was carried out according to the Ethics Committee of Iran’s Ministry of Health and Medical Education guidelines; reference number is not available.

Consent for publication
Written informed consent was obtained from the parents of the patient for publication of this case report.

Competing interests
The authors declared there is no conflict of interest.

Author details
1Department of Genetics, Khuzestan Science and Research Branch, Islamic Azad University, Ahvaz, Iran. 2Department of Genetics, Ahvaz Branch, Islamic Azad University, Ahvaz, Iran. 3Department of Biology, College of Science, University of Basrah, Basrah, Iraq. 4Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Received: 10 June 2021 Accepted: 24 October 2021 Published online: 22 January 2022

References
1. den Hollander AI, Roepman R, Koenekoop RK, Cremers FP (2008) Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res 27(4):391–419. https://doi.org/10.1016/j.preteyeres.2008.05.003
2. Koenekoop RK (2004) An overview of Leber congenital amaurosis: a model to understand human retinal development. Surv Ophthalmol 49(4):379–398. https://doi.org/10.1016/j.survophthal.2004.04.003
3. Imani S, Cheng J, Mobasher-Jannat A, Wei C, Fu S, Yang L et al (2018) Identification of a novel RPGRIP1 mutation in an Iranian family with leber congenital amaurosis by exome sequencing. J Cell Mol Med 22(3):1733–1742. https://doi.org/10.1111/jcmm.13454
4. Foster A, Gilbert C (1992) Epidemiology of childhood blindness. Eye (Lond) 6(2):173–176. https://doi.org/10.1038/eye.1992.34
5. Rim PH, Magna LA, Ramalho AS (2006) Genetics and prevention of blindness. Arq Bras Oftalmol 69(4):481–485. https://doi.org/10.1590/s0004-27492006000400005
6. Tabbara KF, Badr IA (1985) Changing pattern of childhood blindness in Saudi Arabia. Br J Ophthalmol 69(4):312–315. https://doi.org/10.1136/bjo.69.4.312
7. Ibrahim HI, Hidayat HJ (2021) Case report: A GUCY2D gene mutation in Kurdish Nation with Leber congenital amaurosis-1 disease. Ann RSCB 25(4):14049–14054
8. Salehi Chaleshtori AR, Garshasbi M, Salehi A (2019) A novel deletion mutation in GUCY2D gene may be responsible for Leber congenital amaurosis-1 disease: a case report. J Curr Ophthalmol 31(4):458–462. https://doi.org/10.1016/j.jco.2019.07.002
9. Winberg H, Lev D, Yosovich K, Namburi P, Banin E, Sharon D et al (2018) Photoreceptor Guanylate Cyclase (GUCY2D) mutations cause retinal dystrophies by severe malfunction of Ca2+-dependent cyclic GMP synthesis. Front Mol Neurosci 11:348. https://doi.org/10.3389/fnmol.2018.00348
10. García-Hoyos M, Auz-Alexandre CL, Almoguera B, Cantalapiedra D, Rivero-Alvarez R, Lopez-Martinez MA et al (2011) Mutation analysis at codon 638 of the Guanylate Cyclase 2D gene in Spanish families with autosomal dominant cone, cone-rod, and macular dystrophies. Mol Vis 17:1103–1109
11. Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y et al (2014) Molecular findings among patients referred for clinical whole-exome sequencing. JAMA 312(18):1870–1879. https://doi.org/10.1001/jama.2014.14601
12. Chacon-Camacho OF, Zenteno JC. Review and update on the molecular basis of Leber congenital amaurosis. World J Clin Cases. 2015;3(2):112–24. https://doi.org/10.12998/wjcc.v3i2.112
13. Feng X, Wei T, Sun J, Luo Y, Huo Y, Yu P et al (2020) The pathogenicity of novel GUCY2D mutations in Leber congenital amaurosis 1 assessed by HPLC-MS/MS. PLoS ONE 15(4):e0231115. https://doi.org/10.1371/journal.pone.0231115
14. Gradstein L, Zolotushko J, Sergeev YV, Lavy I, Narkin G, Perez Y et al (2016) Novel GUCY2D mutation causes phenotypic variability of Leber congenital amaurosis in a large kindred. BMC Med Genet 17:52. https://doi.org/10.1186/s12881-016-0314-2

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.